The use and safety of Ibuprofen in the hemophiliac.

  title={The use and safety of Ibuprofen in the hemophiliac.},
  author={M. J. Inwood and B. A. Killackey and S J Startup},
After demonstrating initial safety of Ibuprofen administered to hemophiliacs, a 16-wk double-blind individual crossover trial was designed to test the safety and, to a more limited extent, the efficacy of 1600 mg of Ibuprofen or placebo given daily to 20 hemophiliacs with hemophiliac arthropathy. The trial was completed with no evidence of increased frequency or severity of hemophiliac bleeding episodes or clinical or laboratory evidence of bleeding secondary to Ibuprofen. There were five… Expand
Safety profile: fifteen years of clinical experience with ibuprofen.
A careful review of pre-registration and postmarketing data clearly indicates ibuprofen's remarkable safety profile compared with that of aspirin and other commonly prescribed nonsteroidal anti-inflammatory agents. Expand
Hemostatic effects of salsalate in normal subjects and patients with hemophilia A.
It is concluded that this agent may be useful in the treatment of arthritis in patients with hereditary coagulation disorders. Expand
Therapeutics of Ibuprofen in Rheumatic and Other Chronic and Painful Diseases
There is evidence to show that ibuprofen is a safe and effective ‘first-line’ NSAID for many rheumatic patients and mostly it is preferable to paracetamol in osteoarthritis. Expand
Modern management of haemophilic arthropathy.
Currently available factor concentrates for treatment of patients with haemophilia are virally inactivated or are made by recombinant technology and their broad use in developed nations has resultedExpand
Treatment of hemophilic arthritis with D‐penicillamine: A preliminary report
This preliminary study suggests that D‐penicillamine is beneficial in the chronicsynovitis/arthritis induced by hemarthroses and in four hemophiliacs with chronic synovitis. Expand
Choosing and using non‐steroidal anti‐inflammatory drugs in haemophilia
PWH have a higher risk of GI bleeding and lower risk of thrombotic disease compared to general population, so it seems reasonable to use lowest dose of COX‐2 inhibitors for the shortest period together with a proton pump inhibitor when PWH require anti‐inflammatory/analgesic agents. Expand
Clinical challenges within the aging hemophilia population.
Prospective studies are needed to address challenges related not only to hemophilia but also to general comorbidity associated with aging so that evidence-based guidance can be given to clinicians who treat older patients with Hemophilia. Expand
250 Labor and delivery in a patient with hemophilia B Labor and delivery in a patient with hemophilia
Hemophilia B is a rare X-linked disorder that may cause dramatic bleeding. Women account for only 3.2% of those clinically affected. The X-linked inheritance frequently delays the diagnosis in womenExpand
Labor and delivery in a patient with hemophilia B.
A 28-year-old primiparous woman with hemophilia B (bleeding phenotype) delivered a male infant by an unplanned cesarean delivery under general anesthesia following treatment with factor IX and normalization of her coagulation parameters, guided by thromboelastography. Expand
Twenty‐one years of haemophilia
  • D. Evans
  • Medicine
  • Haemophilia : the official journal of the World Federation of Hemophilia
  • 1997
There have been notable advances in treatment, as well as the terrible irony that some therapeutic materials have unwittingly conveyed serious infections, with the result that the survival rates of affected individuals, which became normal, would shorten again. Expand


Effect of ibuprofen on platelet function in normal subjects and hemophiliac patients
The results suggest that ibuprofen may be given to hemophiliac subjects with greater safety than some of the older anti‐inflammatory drugs. Expand
The bleeding time is longer than normal in hemophilia.
The bleeding time is longer than normal in hemophilia, and this abnormality is not related to disease severity, recent transfusions, or the use of nonsteroidal antiinflammatory drugs. Expand
Bleeding times and platelet aggregation after analgesics in hemophilia.
Abstract The effect of aspirin, acetaminophen, propoxyphene, and placebo on the Ivy bleeding time, platelet aggregation, and platelet factor 3 availability was evaluated in a double-blind study of ...
Ethanol potentiation of aspirin-induced prolongation of the bleeding time.
In two subjects who had taken 325 mg of aspirin, a second rise in the bleeding time was observed — at 36 hours after ingestion in one and 60 hours in the other — to levels close to base-line levels. Expand